🔗 Share this article Patients Discontinuing Slimming Jabs Regain Pounds Far More Rapidly Compared to People Using Diet and Exercise Obesity treatment often requires long-term strategies. A recent study indicates that patients who come off popular weight-loss injections like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans. Published data in a leading health publication points out that while overweight individuals can lose about a fifth of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month after stopping. "Individuals buying such medications need to be informed of the potential of quick rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb. Such speed of regain suggests a reversion to starting weight in about a year and a half. Comparing Therapies The research, which examined 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills. The team note that individuals who shed pounds through lifestyle changes alone usually see a more gradual weight regain—approximately 100 grams monthly—after stopping. Explaining the Rapid Regain Experts propose the way of the injections accounts for the heightened rebound. These medications mimic a body's own chemical called GLP-1, which helps regulate appetite. "Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the system to produce less of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher. "Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making overeating a significant risk." A Chronic Disease? The NHS suggest the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications. Professionals contend that, considering the high risk of relapse, the therapy is often long-term. This opinion is reinforced by pharmaceutical companies, who note that the results "highlight the persistent nature of excess weight," similar to managing diseases like high blood pressure. Patient Accounts Users who have discontinued the jabs report a powerful resurgence of appetite. "It was like something that goes on and I was suddenly starving," recalled a patient. This difficulty is compounded if individuals have not developed sustainable dietary or behavioural modifications during therapy. Widespread Interest Survey data suggest that millions of people in the UK have used these injections in the past year, with demand being substantial. Adoption is higher among females compared to men. The 40s and 50s demographic shows the greatest level of interest. A large proportion access the drugs through private prescriptions rather than the NHS. Ultimately, clinicians stress that while these medications are potent tools for shedding pounds, they are not a standalone solution and long-term success hinges on combined behavioural changes.
Obesity treatment often requires long-term strategies. A recent study indicates that patients who come off popular weight-loss injections like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans. Published data in a leading health publication points out that while overweight individuals can lose about a fifth of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month after stopping. "Individuals buying such medications need to be informed of the potential of quick rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb. Such speed of regain suggests a reversion to starting weight in about a year and a half. Comparing Therapies The research, which examined 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills. The team note that individuals who shed pounds through lifestyle changes alone usually see a more gradual weight regain—approximately 100 grams monthly—after stopping. Explaining the Rapid Regain Experts propose the way of the injections accounts for the heightened rebound. These medications mimic a body's own chemical called GLP-1, which helps regulate appetite. "Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the system to produce less of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher. "Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making overeating a significant risk." A Chronic Disease? The NHS suggest the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications. Professionals contend that, considering the high risk of relapse, the therapy is often long-term. This opinion is reinforced by pharmaceutical companies, who note that the results "highlight the persistent nature of excess weight," similar to managing diseases like high blood pressure. Patient Accounts Users who have discontinued the jabs report a powerful resurgence of appetite. "It was like something that goes on and I was suddenly starving," recalled a patient. This difficulty is compounded if individuals have not developed sustainable dietary or behavioural modifications during therapy. Widespread Interest Survey data suggest that millions of people in the UK have used these injections in the past year, with demand being substantial. Adoption is higher among females compared to men. The 40s and 50s demographic shows the greatest level of interest. A large proportion access the drugs through private prescriptions rather than the NHS. Ultimately, clinicians stress that while these medications are potent tools for shedding pounds, they are not a standalone solution and long-term success hinges on combined behavioural changes.